QUIA PHARMA AB Logo

QUIA PHARMA AB

Develops medicines using a proprietary drug delivery platform to improve efficacy.

QUIA | ST

Overview

Corporate Details

ISIN(s):
SE0020678159
LEI:
967600JUP7EI6X9D2Z44
Country:
Sweden
Address:
Virdings Allé 32 B, 754 50 Uppsala

Description

QUIA PHARMA AB is a pharmaceutical development company focused on the research, development, and commercialization of medicines. The company's core activity is based on its proprietary and patented drug delivery platform, Uni-Qleaver®. This platform utilizes a unique, releasable pegylation technology designed to improve the properties of drugs by temporarily modifying them. The Uni-Qleaver® technology aims to enhance the therapeutic efficacy and safety profile of pharmaceuticals by extending their duration of action and enabling the release of the active drug in its original, unmodified form. The company applies this platform to develop improved and patentable versions of existing drugs as well as new chemical entities, with a focus on therapeutic areas such as endocrinology and metabolic diseases.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all QUIA PHARMA AB filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for QUIA PHARMA AB

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for QUIA PHARMA AB via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

NGeneBio Co., Ltd. Logo
Develops NGS-based molecular diagnostic products and software for oncology.
South Korea
354200
Nicox S.A. Logo
Ophthalmology company developing therapies based on a nitric oxide-donating platform.
France
COX
NLS Pharmaceutics Ltd. Logo
Clinical-stage biopharma firm developing therapies for rare and complex CNS disorders.
United States of America
NLSP
NovoCure Ltd Logo
Develops a non-invasive cancer therapy using electric fields to disrupt solid tumors.
United States of America
NVCR
NUFORMIX PLC Logo
Pharmaceutical developer using cocrystal technology to repurpose drugs for fibrosis.
United Kingdom
NFX
Nurix Therapeutics, Inc. Logo
Clinical-stage biopharma developing protein degradation therapies for various diseases.
United States of America
NRIX
OLIPASS CORPORATION Logo
An R&D company developing RNA therapeutics using its proprietary OPNA platform.
South Korea
244460
A technology platform for therapeutic antibody discovery using transgenic animals.
United States of America
OABIW
ONCIMMUNE HOLDINGS PLC Logo
Immunodiagnostics company specializing in antibody and autoantibody biomarker signatures.
United Kingdom
ONC
Oncocross Co.,Ltd. Logo
An AI biotechnology firm that develops drugs by predicting drug-disease interactions.
South Korea
382150

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.